

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

April 23, 2014

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for January 29, 2013 meeting (pages 3-8; Tab 1)
- IV. Secretary's report (page 9; Tab 2)
- V. Old Business
 - A. Updated educational newsletter for Acute Pain Treatment Options (pages 11-12; Tab 3)
 - B. HMO response to DURB follow-up questions regarding protocols (pages 13-15; Tab 4)
- VI. New Business
 - A. Protocols review (pages 17-27; Tab 5)
 1. Ranolazine (Ranexa[®])
 2. Inhalation corticosteroid/Long-acting beta agonists combination (Advair[®]/Dulera[®]/Symbicort[®])
 3. Low Molecular Weight Heparin (LMWH) – enoxaparin (Lovenox[®])
- VII. Informational Highlights/Reports
 1. Molina/NJ HMO 4th Quarter Prior Authorization Report (pages 29-30; Tab 6)
 2. Summary of DURB Recommendations (pages 31-32; Tab 7)
 3. DHS and DHSS Programs Top Drugs Report (pages 33-40; Tab 8)
 4. Medication information: (pages 41-44; Tab 9)
 - (a) FDA: Testosterone Drugs May Increase CV, Death Risk
 - (b) FDA approval of Zohydro[®]
 - (c) Senate Finance Committee Urges CMS to Preserve Mental Health Drug Access (Dr. Gochfeld)